This Harvard Medical School Continuing Education video examines these key questions: How does the World Health Organization (WHO) classify pulmonary hypertension risk categories? What is the role of vasoreactivity testing in determining treatment for pulmonary hypertension? What is the function of tertiary centers for evaluating pulmonary hypertension?

Dr. Jenna McNeill, MD, faculty at Massachusetts General Hospital, discusses how understanding pulmonary hypertension etiologies, as defined by the World Health Organization, aids in determining risk stratification and the role of vasoreactivity testing in recommending appropriate therapies. Approved medications for treating pulmonary arterial hypertension are reviewed as well as appropriate therapies for addressing pulmonary hypertension caused by left heart disease, lung disease, or chronic thromboembolic disease.

00:00 | Introduction
00:26 | World Health Organization functional classifications
00:37 | Recommendations for Group 1
05:06 | Recommendations for Group 2
06:00 | Recommendations for Group 3
07:03 | Recommendations for Group 4

This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.

References:
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016 69(2):177. 

McLaughlin VV, Archer SL, Badesch DB, et al. American College of Cardiology Foundation Task Force on Expert Consensus, A. American Heart, P. American College of Chest, I. American Thoracic Society and A. Pulmonary Hypertension. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17): 1573-1619. 

Thomas CA, Anderson RJ, Condon DF, de Jesus Perez VA. Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. Pulm Ther. 2020;6(1):9-22. 

Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-844. 

Nathan, S. D., A. Waxman and V. Tapson. Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply. N Engl J Med. 2021;384(19): 1871-1872. 

Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-329. 

Notice: At this time, the content in this video is not accredited.

свернуть